Hypothalamic Obesity: Prologue and Promise
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Hypothalamic obesity (HO) frequently occurs following damage to the medial hypothalamic region, encompassing the arcuate nucleus, the paraventricular nucleus, the ventromedial nucleus, the dorsomedial nucleus, and the dorsal hypothalamic area, which are critically involved in the regulation of satiety and energy balance through neural and humoral connections. HO is most commonly described in the context of craniopharyngioma and its treatment, but it can also occur following other suprasellar tumors, radiation, trauma, or a surgical insult to the hypothalamus. A constellation of loss of satiety and a reduction of the metabolic rate, thermogenesis, and physical activity as well as increased vagal tone and hyperinsulinism with insulin and leptin resistance results in rapid weight gain due to a decreased energy expenditure and increased energy storage in adipose cells. To date, no viable long-term solution for HO has been found, due either to the requirement of intact hypothalamic pathways or to significant side effects. Newer therapeutic modalities focused on the unique pathophysiology of this condition offer potential for successful treatment. In this review, we describe the etiology of HO as well as past/current treatment approaches in the categories of hyperinsulinism, surgical approaches, and targeting energy expenditure/anorectic drugs. We conclude by providing an overview of the clinical trials currently underway.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“From a hormone output standpoint, hypothalamic dysfunction may alter hormone release potentially applicable to body composition and body weight, such as corticotrophin-releasing hormone, dopamine, growth hormone-releasing hormone, somatostatin, gonadotrophin-releasing hormone, and thyrotrophin-releasing hormone [21].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [21]
In the citing paper
“Largely through the vagus nerve, afferent stomach stretch-fibers after a meal transmit parasympathetic signals to the brain and hypothalamus to increase satiety.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [21]
In the citing paper
“Hypothalamic efferent signals to other parts of the brain may affect hunger and appetite, and may affect thermogenesis, energy expenditure, increase blood pressure, and stimulate lipolysis in adipose tissue [21].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [21]
In the citing paper
“From a hormone input standpoint, ghrelin from the stomach increases hunger.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [21]
In the citing paper
“Leptin from adipose tissue may also decrease hunger.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [21]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Jung, U., & Choi, M.-S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046184 · Cited by 1,880
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943
Acute and Chronic Effect of Insulin on Leptin Production in Humans: Studies In Vivo and In Vitro
Kolaczynski, J. W., Nyce, M. R., Considine, R. V., Boden, G., Nolan, J. J., Henry, R., Mudaliar, S. R., Olefsky, J., & Caro, J. F. (1996) · Diabetes · doi:10.2337/diab.45.5.699 · Cited by 700
Müller, H. L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1115 · Cited by 401
Müller, H. L., Gebhardt, U., Teske, C., Faldum, A., Zwiener, I., Warmuth-Metz, M., Pietsch, T., Pohl, F., Sörensen, N., & Calaminus, G. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0158 · Cited by 302
Octreotide Therapy of Pediatric Hypothalamic Obesity: A Double-Blind, Placebo-Controlled Trial
Lustig, R. H., Hinds, P. S., Ringwald-Smith, K., Christensen, R. K., Kaste, S. C., Schreiber, R. E., Rai, S. N., Lensing, S. Y., Wu, S., & Xiong, X. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030003 · Cited by 299
Müller, H. L., Bueb, K., Bartels, U., Roth, C., Harz, K., Graf, N., Korinthenberg, R., Bettendorf, M., Kühl, J., Gutjahr, P., et al. (2001) · Klinische Pädiatrie · doi:10.1055/s-2001-16855 · Cited by 273
Self-citationLeptin action in the forebrain regulates the hindbrain response to satiety signals
Morton, G. J., Blevins, J. E., Williams, D. L., Niswender, K. D., Gelling, R. W., Rhodes, C. J., Baskin, D. G., & Schwartz, M. W. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522081 · Cited by 256
BRAY, G. A., & GALLAGHER, T. F. (1975) · Medicine · doi:10.1097/00005792-197507000-00002 · Cited by 231
Pereira, A. M., Schmid, E. M., Schutte, P. J., Voormolen, J. H. C., Biermasz, N. R., Van Thiel, S. W., Corssmit, E. P. M., Smit, J. W. A., Roelfsema, F., & Romijn, J. A. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02196.x · Cited by 220
Cited by
Frappaz, D., Dhall, G., Murray, M. J., Goldman, S., Faure‐Conter, C., Allen, J. C., Kortmann, R. D., Haas-Kogen, D. A., Morana, G., Finlay, J. L., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab252 · Cited by 169
Roth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87
“The Energy Balance and Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumours in Hypothalamic Obesity (ECHO) trial was an investigator-initiated multisite, 36-week, double-blind, placebo-controlled randomized trial to evaluate the efficacy and safety of ExQW for BMI reduction in adolescents and young a…”
InfluentialSelf-citationRoth, C. L., Scimia, C., Shoemaker, A. H., Gottschalk, M., Miller, J., Yuan, G., Malhotra, S., & Abuzzahab, M. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00087-1 · Cited by 76
Self-citationTheilade, S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14270 · Cited by 82
“Hypothalamic lesions can cause rapidly progressive, severe obesity, which is particularly difficult to treat.(198) Hypothalamic obesity can develop after traumas, tumours or inflammatory diseases perturbing hypothalamic function.”
BackgroundBays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
“Conversely, hormones such as insulin (i.e., from pancreatic beta cells), amylin (i.e., from pancreatic beta cells), and glucagon (i.e., from pancreatic alpha cells), CCK from the small intestine, and GLP-1, oxy-ntomodulin, PYY, and FGF19 from the ileum or large intestine may all reduce hunger [21].”
BackgroundInfluentialNeuro-Vulnerability in Energy Metabolism Regulation: A Comprehensive Narrative Review
Clemente‐Suárez, V. J., Beltrán-Velasco, A. I., Redondo-Flórez, L., Martín-Rodríguez, A., Sepulveda, R. A. Y., & Tornero-Aguilera, J. F. (2023) · Nutrients · doi:10.3390/nu15143106 · Cited by 50
“It is a peptide containing 167 amino acids and is essential in understanding energy balance [99,100].”
BackgroundShoemaker, A. H., Silver, H. J., Buchowski, M., Slaughter, J. C., Yanovski, J. A., Elfers, C., Roth, C. L., & Abuzzahab, M. J. (2022) · International Journal of Obesity · doi:10.1038/s41366-021-01043-6 · Cited by 38
“DISCUSSION HO is a refractory form of obesity thought to be due to a combination of decreased energy expenditure and increased food intake [19].”
BackgroundSelf-citationMcCormack, S. E., Wang, Z., Wade, K. L., Dedio, A., Cilenti, N., Crowley, J., Plessow, F., Bamba, V., Roizen, J. D., Jiang, Y., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad037 · Cited by 37
“Hypothalamic obesity is a rare form of treatment-resistant obesity that frequently develops in individuals with brain tumors affecting the hypothalamus and pituitary, such as craniopharyngioma [1, 2].”
BackgroundCurrent and future state of pharmacological management of pediatric obesity
Fox, C. K., Kelly, A. S., Reilly, J. L., Theis-Mahon, N. R., & Raatz, S. J. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01465-y · Cited by 43
“Tumor invasion or treatment damages hypothalamic nuclei that control satiety and energy expenditure [53].”
Targeting Energy Expenditure—Drugs for Obesity Treatment
Jimenez-Munoz, C. M., López, M., Albericio, F., & Makowski, K. (2021) · Pharmaceuticals · doi:10.3390/ph14050435 · Cited by 35
“Furthermore, caffeine and ephedrine have been used in combination to induce weight loss through increased energy expenditure and reduced appetite by binding to the βadrenergic receptor (ephedrine) and adenosine receptor (caffeine) [38].”
BackgroundObesity in children and adolescents: Overview of the diagnosis and management
Tung, J. Y., Poon, G. W.-K., Du, J., & Wong, K. K. Y. (2023) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.58 · Cited by 42
“Patients typically have a loss of satiety and a reduced metabolic rate.(29) Therefore, the treatment strategy would be different from that for children with simple obesity.”
BackgroundPostoperative and Long-Term Endocrinologic Complications of Craniopharyngioma
Bereket, A. (2020) · Hormone Research in Paediatrics · doi:10.1159/000515347 · Cited by 40
Gatta‐Cherifi, B., Mohammedi, K., Cariou, T., Poitou, C., Touraine, P. A., Raverot, G., Brue, T. C., Chanson, P., Illouz, F., Grunenwald, S., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae024 · Cited by 29
Craniopharyngiomas primarily affecting the hypothalamus
Pascual, J. M., Prieto, R., & Rosdolsky, M. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-820683-6.00007-5 · Cited by 31
Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon
Roth, C. L., & Zenno, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1256514 · Cited by 29
Self-citationApproach to the Patient With Hypothalamic Obesity
Shoemaker, A. H., & Tamaroff, J. G. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac678 · Cited by 30
Self-citationTreatment of Hypothalamic Obesity With GLP-1 Analogs
Dimitri, P., & Roth, C. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae200 · Cited by 25
Self-citationRadiotherapy alone for pediatric patients with craniopharyngioma
Young, M., Delaney, A., Jurbergs, N., Pan, H., Wang, F., Boop, F. A., & Merchant, T. E. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03908-2 · Cited by 25
Guo, Y., Pei, L., Li, Y., Li, C., Gui, S., Ni, M., Liu, P., Zhang, Y., & Zhong, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1180591 · Cited by 28
Craniopharyngiomas: Challenges and Controversies
Asha, M. J., Oswari, S., Takami, H., Velásquez, C., Almeida, J. P., & Gentili, F. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.05.172 · Cited by 23
A Survey of Patient-Relevant Outcomes in Pediatric Craniopharyngioma: Focus on Hypothalamic Obesity
Craven, M., Crowley, J. H., Chiang, L., Kline, C., Malbari, F., Hocking, M. C., & McCormack, S. E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.876770 · Cited by 21
“Hypothalamic obesity is often refractory to conventional obesity treatments, although a multi-pronged approach may yield modest benefits as suggested by the available evidence base (10, 11).”
BackgroundHeymsfield, S. B., Clément, K., Dubern, B., Goldstone, A. P., Haqq, A. M., Kühnen, P., Richards, J. R., Roth, C. L., van den Akker, E. L. T., Wabitsch, M., et al. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00601-z · Cited by 25
“…to a preoccupation with food • Emotional dysregulation when denied access to food (i.e., tantrums, irritability) Hypotha-lamic obesity [9, 11, 28, 36–42] • Dysregulated circulating α-MSH due to damage of central hypothalamic centers that regulate its production • Preoccupation with food •…”
Self-citationPartenope, C., Pozzobon, G. C., Weber, G., Arya, V. B., Carceller, F., & Albanese, A. (2022) · Endocrine · doi:10.1007/s12020-022-03121-9 · Cited by 22
“Research into new therapeutic approaches is needed [38].”
Hamblin, R., Tsermoulas, G., & Karavitaki, N. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104078 · Cited by 22
van Roessel, I. M. A. A., van den Brink, M. R. M., Dekker, J., Essen, B. G. R.-V., Tissing, W. J. E., & van Santen, H. M. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.05.028 · Cited by 21
Epistaxis: a review of hospitalized patients.
Huang, C.-L., & Shu, C. (2002) · PubMed · Cited by 17
Resting energy expenditure in children at risk of hypothalamic dysfunction
Van Schaik, J., Burghard, M., Lequin, M. H., van Maren, E. A., van Dijk, A. M., Takken, T., Rehorst-Kleinlugtenbelt, L. B., Bakker, B., Meijer, L., Hoving, E. W., et al. (2022) · Endocrine Connections · doi:10.1530/ec-22-0276 · Cited by 13
“Additionally, the disruption of autonomic function damages the biologic clock and therefore the circadian activity (13).”
A novel MYT1L mutation in a boy with syndromic obesity: Case report and literature review
Carvalho, L. M. L., D’Angelo, C. S., Mustacchi, Z., da Silva, I. T., Krepischi, A. C. V., Koiffmann, C. P., & Rosenberg, C. (2021) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2021.01.001 · Cited by 14
Macías-Triana, L., Romero-Cordero, K., Tatum-Kuri, A., Vera-Barrón, A., Millán‐Aldaco, D., Arankowsky‐Sandoval, G., Piomelli, D., & Murillo‐Rodríguez, E. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.172911 · Cited by 14
Witte, J., Surmann, B., Batram, M., Weinert, M., Flume, M., Touchot, N., Beckhaus, J., Friedrich, C., & Muller, H. L. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13439 · Cited by 15
Kothari, V., Cardona, Z., & Eisenberg, Y. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-820683-6.00019-1 · Cited by 17
Multidisciplinary Approach for Hypothalamic Obesity in Children and Adolescents: A Preliminary Study
Tessaris, D., Matarazzo, P., Tuli, G., Tuscano, A., Rabbone, I., Spinardi, A., Lezo, A., Fenocchio, G., Buganza, R., & de Sanctis, L. (2021) · Children · doi:10.3390/children8070531 · Cited by 11
“The nuclei that seem most commonly implicated in HO are the arcuate nucleus, the paraventricular nucleus, the ventromedial nucleus, the dorsomedial nucleus, and the dorsal hypothalamic area [7].”
BackgroundResultInfluentialArgente, J., Clément, K., Duis, J. B., Farooqi, I. S., Kühnen, P., Miller, J. L., Roth, C. L., & van den Akker, E. L. T. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09984-3 · Cited by 13
“Critically, challenges with weight management increase the risk and severity of obesity, obesity-related comorbidities, and premature death [25, 57–59], which may be further heightened in patients with rare MC4R pathway diseases [1, 3, 57, 60–63].”
InfluentialSelf-citationCuda, S. E., Censani, M., O’Hara, V. M., Paisley, J., Kharofa, R. Y., Conroy, R., Sweeney, B. R., Fernández, C., Gillette, M. L. D., & Browne, N. T. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100113 · Cited by 13
“The inability to reduce weight is thought to be due to the decrease in metabolic rate and thus energy expenditure [141].”
InfluentialImproving the diagnosis of hyperphagia in melanocortin‐4 receptor pathway diseases
Abuzzahab, M. J., Dubern, B., Goldstone, A. P., Haqq, A. M., Heymsfield, S. B., Miller, J. L., Richards, J. R., Wabitsch, M., & Yanovski, J. A. (2025) · Obesity · doi:10.1002/oby.24287 · Cited by 10
Self-citationThe Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies
Tonin, G., Eržen, S., Mlinarič, Z., Jurišić‐Eržen, D., Horvat, S., Kunej, T., & Klen, J. (2025) · Obesity Reviews · doi:10.1111/obr.13978 · Cited by 18
Muller, H. L., Witte, J., Surmann, B., Batram, M., Braegelmann, K., Flume, M., Beckhaus, J., Touchot, N., & Friedrich, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-85262-1 · Cited by 10
Adult-Onset CNS Sulfatide Deficiency Causes Sex-Dependent Metabolic Disruption in Aging
Qiu, S., He, S., Wang, J., Wang, H., Bhattacharjee, A., Li, X., Saeed, M., Dupree, J. L., & Han, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310483 · Cited by 7
Порсева, В. В., Levshin, N. Y., Moiseev, K. Y., Pankrasheva, L. G., Baranov, A. A., Pavlov, A. V., Ad, N., & Masliukov, P. M. (2021) · Advances in Gerontology · doi:10.1134/s207905702104010x · Cited by 8
Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity
Roth, C. L., Doelman-Oldenburger, N. J., & van Santen, H. M. (2026) · Drugs · doi:10.1007/s40265-025-02280-z · Cited by 7
Self-citationThe Interaction of Obesity and Reproductive Function in Adolescents
Elliott, V., Waldrop, S., Wiromrat, P., Carreau, A., & Cree‐Green, M. (2022) · Seminars in Reproductive Medicine · doi:10.1055/s-0042-1744495 · Cited by 8
Magerman, C., Boros, E., Preziosi, M., Lhoir, S., Gilis, N., Witte, O. D., Heinrichs, C., Salmon, I. J., Fricx, C., Vermeulen, F., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1297132 · Cited by 12
“Various drugs have been proposed, including methylphenidate, oxytocin, metformin, and GLP1 analogs (33), though these pharmacological treatments are still debated (34).”
BackgroundPapy, M., Jacobs, S. A., & Rochtus, A. M. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0275 · Cited by 7
Witte, J., Touchot, N., Surmann, B., Braegelmann, K. A., Flume, M., Beckhaus, J., Friedrich, C., & Muller, H. L. (2025) · The European Journal of Health Economics · doi:10.1007/s10198-025-01786-3 · Cited by 7
“The most common causes of acquired hypothalamic damage are space-occupying lesions, such as craniopharyn-giomas and pituitary macroadenomas, with sellar/suprasel-lar extension and invasion of the hypothalamic nuclei [8].”
Could deep brain stimulation be a possible solution for acquired hypothalamic obesity?
Dassen, A. R., van Schaik, J., van den Munckhof, P., Schuurman, P. R., Hoving, E. W., & van Santen, H. M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14411 · Cited by 4
“Bariatric surgery appeared most effective, but has a high rate of relapse on the long term and has its ethical concerns among children [16,18,23].”
BackgroundShirozu, H., Masuda, H., & Kameyama, S. (2024) · Journal of neurosurgery · doi:10.3171/2024.7.jns24560 · Cited by 6
Witte, J., Touchot, N., Batram, M., Diekmannshemke, J., Flume, M., & Muller, H. L. (2025) · Journal of Neuroendocrinology · doi:10.1111/jne.70108 · Cited by 5
Kayadjanian, N., Hsu, E. A., Wood, A. M., & Carson, D. S. (2026) · Scientific Reports · doi:10.1038/s41598-026-45789-3 · Cited by 4
Metabolic syndrome as a common comorbidity in adults with hypothalamic dysfunction
Xu, Z., Ke, X., Yuan, X., Wang, L., Duan, L., Yao, Y., Deng, K., Feng, F., You, H., Lian, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.973299 · Cited by 5
Xiang, B., Sun, Q., He, M., Wu, W., Lü, B., Zhang, S., Zhang, Z., Yang, Y., Li, Y., Wu, Y., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.693669 · Cited by 2
Infantile Hypothalamic Hamartoma: A Rare Presentation of Isolated Obesity
Tsumori, M., Itonaga, T., Oyake, M., Hirano, N., Oyama, N., & Ihara, K. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luae033 · Cited by 2
“…rapid weight gain due to decreased energy expenditure and increased energy storage in adipose cells can occur from combinations of a reduction in metabolic rate, increased vagal tone, hyperinsulinism with leptin resistance, or sleep disturbance, irrespective of the patient’s age [8, 13-16].”
BackgroundComplex Long-term Effects of Radiation on Adult Mouse Behavior
Garrett, L., Ung, M.-C., Einicke, J., Zimprich, A., Fenzl, F. Q., Pawliczek, D., Graw, J., Dalke, C., & Hölter, S. M. (2021) · Radiation Research · doi:10.1667/rade-20-00281.1 · Cited by 3
Nezu, M., Kudo, M., Ono, Y., Tezuka, Y., Morimoto, R., Sawada, S., Imoto, H., Naitoh, T., Katagiri, H., Ito, S., et al. (2019) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.249.223 · Cited by 1
Paediatric craniopharyngiomas – Treatment outcomes based on when radiotherapy was given
How, E., Maclachlan, L., & Campbell, R. (2022) · Interdisciplinary Neurosurgery · doi:10.1016/j.inat.2022.101574 · Cited by 1
Obesity in childhood and adolescence
Gesing, J. K., & Kieß, W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00064-9 · Cited by 1
Obesità post-neurochirurgia ipotalamica
Bo, S., Ponzo, V., Pellegrini, M., & Grottoli, S. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00834-3
Marina, M., Guitter, M. R., Rossi, J., Latella, A., & Felice, M. S. (2021) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2021.e242
Ablação estereotáctica de hamartomas hipotalâmicos para o tratamento de crises epilépticas
Sepulveda, M. E. S. M. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-23072021-105940
Craneofaringioma como causa de obesidad central: Reporte de caso y revisión de literatura
Bobadilla-Olaje, G. F., Calleja-López, J. R. T., Aguilera-Duarte, L. J., Ruibal-Tavares, E., Rivera-Rosas, C. N., & Ocampo-Verduzco, J. C. (2021) · REMUS - Revista Estudiantil de Medicina de la Universidad de Sonora · doi:10.59420/remus.6.2021.18
Karsy, M. J., & Evans, J. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-99321-4_18
Childhood Neoplasms and Impact on Hormones
Hoyos-Martínez, A., & Horne, V. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_3
Carvalho, L. M. L. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2023.tde-23032023-174554
Hypothalamic-pituitary dysfunction in children with suprasellar tumors: improving the outcome
van Schaïk, J. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1959
Novel therapeutic approaches for pediatric diencephalic tumors: improving functional outcomes
Cockle, J. V., Corley, E. A., Zebian, B., Hettige, S., Vaidya, S. J., Angelini, P., Stone, J., Leitch, R. J., Albanese, A., Mandeville, H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1178553 · Cited by 1
Features of reproductive function and IVF programs in patients with overweight and obesity
Kraevaya, E. E. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-480 · Cited by 1
Inflammation Resolution and Its Relevance to Metabolic Syndrome
Jain, M. R., & Joharapurkar, A. A. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-75686-3_10 · Cited by 1
Guo, Y., Gui, S., Liu, P., Zhang, Y., Zhong, L., & Xu, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1615720 · Cited by 2
Xia, J., Li, J., Chen, S., Chang, T., Qian, Y., Wu, O., Wu, Y., Zhao, Y., Hao, J., & Zhong, L. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.01.080
Muller, H. L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1895026 · Cited by 1
“Hypothalamic obesity – as a part of hypothalamic syndrome - refers to excessive weight gain resulting from disruption of hypo-thalamic pathways that regulate satiety and energy homeostasis (36, 37).”
IMPROVE 2025: The 3rd International Meeting on Pathway‐Related Obesity: Vision & Evidence
Argente, J., van den Akker, E. L. T., Cetiner, M., Clément, K., Forsythe, E. L., Garfield, A. S., Kühnen, P., Martos‐Moreno, G. Á., Meeker, D., Muller, H. L., et al. (2026) · Clinical Obesity · doi:10.1111/cob.70109
“…glioma, after which patients may develop pituitary insufficiency, behavioural problems, hyperphagia, morbid obesity, hypothermia and sleep problems [58–60]. aHO is characterised by hyperphagia with accelerated and sustained weight gain, but is often accompanied by neurobehavioural and psychiatric…”
Gupta, K., Zeinali, M., Altschul, D., Agarwal, V. J., & Karsy, M. J. (2026) · Pituitary · doi:10.1007/s11102-026-01760-z
“Pharmacological approaches (GLP-1 agonists, metformin) yield modest results, necessitating multimodal strategies [6, 79 ].”
Influential
Metadata
- Authors
- Abuzzahab, M. J., Roth, C. L., & Shoemaker, A. H.
- Affiliations
- Children’s Minnesota - St. Paul Hospital (US)
- University of Washington (US)
- Vanderbilt University Medical Center (US)
- Corresponding author
- Abuzzahab, M. Jennifer
- Venue
- Hormone Research in Paediatrics
- Publisher
- S. Karger AG
- Published
- 2019
- Volume
- 91
- Issue
- 2
- Pages
- 128-136
- ISSN
- 1663-2818 (ISSN-L)
- 1663-2826
- OpenAlex
- W2921581269
- Cited by
- 71
- References
- 67
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 14 · 2023: 10 · 2022: 11 · 2021: 16 · 2020: 4 · 2019: 1
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Hormone Research in Paediatrics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK104936)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- hypothalamic obesity, craniopharyngioma, hypothalamic injury, satiety regulation, energy balance, hyperinsulinism, leptin resistance, energy expenditure, anorectic drugs, surgical treatment, hypothalamic tumors, weight gain
- MeSH terms
- Animals, Arcuate Nucleus of Hypothalamus, Craniopharyngioma, Energy Metabolism, Humans, Obesity, Paraventricular Hypothalamic Nucleus, Pituitary Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.